Fig. 6From: Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K studyHypoglycemia in patients receiving sitagliptin plus SU therapy during the 2-year observation periodBack to article page